Entries by Thomas Gabrielczyk

Pharma industry calls EU pharma package counterproductive

Pharmaceutical associations have responded with sharp criticism to the adoption of the revised general pharmaceutical legislation by the EU Council of Ministers in the form of a directive and a regulation. They argue that the measures are not suitable for bringing Europe back to the forefront of pharmaceutical research and will make the EU an unattractive location for investment.

Super deal for BioNTech – BMS licenses potential blockbuster for €10bn

In the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.

Scotland’s bioeconomy gets scale-up boost

Scotland’s biotechnology sector is celebrating a major milestone with the launch of the nation’s first open-access 300-litre fermenter – a state-of-the-art piece of equipment that will support early-stage companies to develop bio-based products at scale.

Reproducible nanopore sequencing to be commercialised from 2026

For nearly two decades, Roche AG has been searching for a next-generation sequencing method in personalised medicine to overcome the limitations of short read lengths in existing sequencing technologies. Following beta testing, the company plans to launch its new Sequencing by Expansion (SBX) technology commercially next year.

Biopharma transformation: leading drug discovery start-ups of 2025

British company Wildcat Laboratory Solutions Ltd and Hamburg-based mo:re GmbH have received the New Product Award from the Society for Laboratory Automation and Screening (SLAS) in recognition of new technologies with potential to drive industry transformation. The award for the most promising start-up was conferred upon Swiss firm Oryl Photonics SA.